All In Biotech

Drug Trial Radar · NCT05739123

Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring

Last checked: Nov 20, 2026Latest source record: Aug 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

728

Planned (sponsor's estimate)

Start

May 8, 2023

Primary completion

May 2033

Study completion May 2033

Sponsor

Sponsor type
Industry
First posted
Feb 22, 2023

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
Female only, from 0 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Relugolix Pregnancy Registry is a prospective, observational cohort study designed to evaluate the association between relugolix-containing therapy exposure during pregnancy and subsequent maternal, fetal, and infant outcomes. Data will be collected from enrolled pregnant women and the healthcare providers (HCPs) involved in their care or the care of their infants, if applicable.

Conditions

  • Pregnancy Related
  • Pregnancy Complications
  • Pregnancy, High Risk

Interventions

  • Relugolix-Containing ProductDrug

    Any relugolix-containing therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major Congenital Malformation (MCM)Time frame: Up to 10 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PPD

    Wilmington, North Carolina · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.